“Antibody testing is key to understanding the prevalence of COVID-19 in our Canadian communities and, although complicated laboratory solutions are available to accomplish this, rapid testing offers an easy and inexpensive option to healthcare professionals and public health organizations.” saidTim Salter, President of Verify Diagnostics. “Use of these rapid tests have been proven effective in dozens of countries that we have provided solutions to and we are very happy to be able to now provide a solution forCanada.”.Verify Diagnostics has promoted the use of antibody tests globally since the beginning of the pandemic as a way to measure the disease’s spread through communities and, more recently, to track the efficacy of vaccination programmes. “One of the unknowns related to SARS-CoV-2 vaccines is how long the immunization will remain effective against the virus.” said Salter. “We hope thatCanadawill follow suit with some of the other governments and organizations that we are working with to monitor those that have received inoculations to better understand how long immunity against the virus will last.”.Appropriate training is also an important factor in ensuring that rapid tests are both used properly and interpreted correctly. “We have invested significant resources into creating multilingual online courses for all of the testing solutions we offer, including COVID-19 tests.” said Salter. “There’s a difference between selling a product and providing a solution, we have always focussed on the latter.”.About Verify DiagnosticsBased inBarrie, Ontario, CanadaVerify Diagnostics is focussed on delivering innovative point-of-care solutions with specialities in drugs of abuse, fertility and infectious disease testing.
SOURCE Verify Diagnostics Inc.View original content to download multimedia:http://www.newswire.ca/en/releases/archive/February2021/16/c5919.html